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Background: The diagnosis and management of BK virus (BKV) reactivation following renal transplantation
continues to be a significant clinical problem. Following reactivation of latent virus, impaired cellular immunity
enables sustained viral replication to occur in urothelial cells, which potentially leads to the development of BKV-
associated nephropathy (BKVAN). Current guidelines recommend regular surveillance for BKV reactivation through
the detection of infected urothelial cells in urine (decoy cells) or viral nucleic acid in urine or blood. However, these
methods have variable sensitivity and cannot routinely distinguish between different viral subtypes. We therefore
asked whether mass spectrometry might be able to overcome these limitations and provide an additional non-
invasive technique for the surveillance of BKV and identification of recipients at increased risk of BKVAN.
Results: Here we describe a mass spectrometry (MS)-based method for the detection of BKV derived proteins
directly isolated from clinical urine samples. Peptides detected by MS derived from Viral Protein 1 (VP1) allowed
differentiation between subtypes I and IV. Using this approach, we observed an association between higher decoy
cell numbers and the presence of the VP1 subtype Ib-2 in urine samples derived from a cohort of 20 renal
transplant recipients, consistent with the hypothesis that certain viral subtypes may be associated with more severe
BKVAN.
Conclusions: This is the first study to identify BK virus proteins in clinical samples by MS and that this approach
makes it possible to distinguish between different viral subtypes. Further studies are required to establish whether
this information could lead to stratification of patients at risk of BKVAN, facilitate distinction between BKVAN and
acute rejection (AR), and ultimately improve patient treatment and outcomes.
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BK virus, a member of the polyomavirus family, infects the
majority of the population during childhood [1]. In most
cases infection is asymptomatic; however, BKV persists in
the urothelial tract with intermittent reactivation occurring
throughout life [2,3]. In the presence of immuno-
suppression sustained viral replication may occur due to
escape of the endogenous virus from immune control or in
renal transplant recipients through co-infection with virus
of donor origin [4,5]. If viral replication remains uncon-
trolled, lytic destruction of infected cells occurs, eventually* Correspondence: bmk@ccmp.ox.ac.uk; cpugh@well.ox.ac.uk
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reproduction in any medium, provided the ordisturbing kidney function, and resulting in the characteris-
tic biopsy appearances of BK-virus associated nephropathy
(BKVAN) [6]. Distinguishing between acute rejection and
BKVAN is important, because although the histological
appearances may be similar, graft rejection necessitates
increased immunosuppression, whereas control of BK viral
replication requires immunosuppression reduction. Overall,
improving the subject’s clinical status requires care in
achieving a balanced immunosuppressive regimen, particu-
larly as there is an inevitable lag between changes in drug
therapy and clinical response.
Screening for BK virus in kidney transplant recipients
is usually carried out by the detection of virally infected
cells in urine or viral nucleic acid in urine or blood [7].
Urine cytology is often used as a screening test for active
viral infection by looking for decoy cells; urothelial cellsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical Data of study subjects






1 60 M 112 32 5.25
2 43 F 113 433 7.5
3 53 F 95 382 6.5
4 52 M 163 209 2.5
5 41 F 364 1597 7
6 29 M 108 191 3
7 62 M 230 63 6.5
8 48 M 118 119 2.5
9 72 M 200 246 2.5
10 47 M 112 238 4
11 32 F 113 459 2
12 47 F 163 224 10
13 72 M 139 63 4
14 58 F 73 340 3
15 42 M 164 235 7.8
16 49 M 122 333 4.5
17 54 M 129 994 2.5
18 66 M 135 344 5
19 49 F 99 21 6
20 39 M 118 142 3.5
This study was based on 20 subjects who had received renal transplants for end-
stage renal failure. They had an average age of 50.75 and a range of 29-72 years
(Table 1); 65% were male. The average serum creatinine level was 143.5 µmol / L
and the range was 73-364 µmol / L at the time point of collection. The average
collection day post-transplant was 333.25 days and the range was 21-1597 days.
Immunosuppressant therapies were defined using the Vasudev Index [29].
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philic intra-nuclear inclusion [8]. However, the sensitiv-
ity and specificity of decoy cell measurement is debated
[9-13]. BK viral DNA in urine or plasma samples can be
measured to determine viral load, but detection depends
on the primer used and does not usually distinguish the
subtypes [12]. However, despite monitoring the trans-
plant recipient’s kidney function, decoy cell counts, and
viral load in plasma / urine samples, characterizing the
degree of BKVAN remains a challenge. To overcome
this, a number of other techniques are under evaluation.
Serological testing is problematic due to the high back-
ground level of sero-positivity, which is in itself insuffi-
cient to prevent disease. Assays for the assessment of
BKV-specific T-cell responses remain experimental [14].
Urine electron microscopic detection of viral aggregation
has been reported to be highly sensitive and specific but is
complex to perform and not used routinely [15]. Most re-
cently BK viral genotyping by high-resolution melting ana-
lysis has been described [16]. Despite all these options
repeated renal biopsies are sometimes required. However,
even with this invasive approach evaluation remains diffi-
cult due to patchy infection and the overlap in histological
appearances between BKVAN and acute rejection.
BK viruses have evolved into four serologically distinct
subtypes (I–IV). Furthermore, subtype I can be divided into
Ia, Ib-1, Ib-2 and Ic. The genome sequence of Ia (Dunlop
strain) was first described by Seif et al., 1979 [17]. DNA iso-
lated from urine of BKVAN subjects has shown mutations
encoding amino acid substitutions throughout the highly
variable major capsid viral protein VP1; the protein respon-
sible for attachment to and subsequent infection of the host
cell via an α-(2,3)-linked sialic acid on N-linked glycopro-
teins [18-20]. Longitudinal analyses of kidney biopsies have
also shown changes in the VP1 sequence within individual
subjects [21]. Although correlations between BKV subtypes
and clinical outcome remain controversial [22], some previ-
ous studies indicate that certain subtypes may cause more
complications than others [23].
Non-invasive routes to analyze the presence of different
BK viral subtypes may enhance our understanding of the
general pathology of BK viruses and provide new entry
points to address the problem of BKVAN.
In the present pilot study, we developed a mass spec-
trometry-based method to identify and characterize BKV
proteins in urine samples from renal transplant subjects.
Our results demonstrated the identification of BK virus
subtypes and provided evidence of co-infection in several
patients.
Results and discussion
In this pilot clinical study urine samples from 20 renal
transplantation recipients (Table 1) were analyzed for BK
viral protein content via mass spectrometry. In our unitdecoy cell assessment is routinely and cost effectively used
to detect BK viral infection [24]. Fourteen of these patients
were selected because of current or recent decoy cell
positivity, whereas the other six patients were selected as
negative controls on the basis that they had never had
decoy cells detected in their urine. Serum creatinine levels
were assayed to assess kidney function at the time of collec-
tion and averaged 143.5 μmol / L with a range of 73–364
μmol / L. The normal range for creatinine levels observed
in people with healthy kidney function in our hospital is
between 54–145 μmol /L.
Initial studies on unfractionated urine did not lead to the
identification of BK viral peptides by mass spectrometry
(results not shown). A differential centrifugation-based
separation and enrichment protocol was therefore
developed (see Figure 1) which did allow identification of a
variety of viral peptides in the different fractions. Although
slightly complex, this workflow allowed distinction between
viral material in urinary cells (cellular fraction) and within
the supernatant between intact virus (intact virus fraction)
and viral material released following cell lysis (released viral
material fraction). The approach described may allow
Figure 1 Centrifugation-based separation and enrichment workflow of urine samples. Urine samples were separated via centrifugation into
three fractions: a cellular fraction containing epithelial cells pelleted by centrifugation, an intact virus fraction generated via ultracentrifugation through a
10% sucrose cushion and the ultracentrifugation supernatant was concentrated by a 5 kDa cut off filter to produce a fraction containing released viral
material. Proteins from all fractions were methanol / chloroform precipitated and in-solution digestion was carried out followed by LC-MS/MS analysis.
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lial shedding is prominent, effective on-going viral replica-
tion is occurring and the destructive aspects of cellular
infection remain unchecked respectively.
Fractionated urine samples were subjected to analysis by
LC-MS/MS tandem mass spectrometry and the observed
peptides were searched against a customized database
where BK viral protein sequences from different subtypes
were combined with a human database. One limitation of
mass spectrometry is a bias towards the detection and iden-
tification of the most abundant analyte in a given sample. It
is therefore not surprising that the highest viral protein
coverage in samples assessed to be BKV positive by decoy
cell count was of the BKV protein VP1, a high copy
number constituent of viral particles. This viral protein was
mainly found in the released viral material fraction, perhaps
reflecting the virus’ lytic properties, but it was also identi-
fied in the cellular fraction of some of the BKV positive
samples, despite the more complex protein content of this
fraction. In contrast, the Large T protein was only
detectable in some of the released viral material fractions
(unpublished data).The BK viral VP1 protein sequence is known to be highly
variable between viral subtypes. To detect the different BK
virus subtypes in the renal transplant recipients the BKV
positive samples were further analyzed with respect to VP1
sequence coverage, the number of peptides found derived
from this protein and links between the observed peptides
and the known viral subtypes. Although the BKV VP1 pro-
tein (Swiss Prot Acc No: P03088) shares similarities
between JC (P03089), SV40 (P03087), Merkel cell polyoma-
virus (B6DVZ3), WU polyomavirus (A5HBD5) and KI
polyomavirus of 78.2%, 81.5%, 43.9%, 28.8% and 28.1%,
respectively the peptide fragment presented in Figure 2 is
unique to BKV VP1. In this peptide (aa 39–63) amino acid
substitutions at 41, 60 and 61 distinguish between groups
containing subtypes Ia, Ib-1 and Ic, subtype Ib-2 or subtype
IV (Figure 2). Of the thirteen BKV positive samples,
analysis of the most abundant peptides detected showed
four of these individuals were infected with the Ib-2 strain,
two individuals were infected with strain IV, one subject
was Ib-1 positive and one subject was infected with the Ic
subtype. Peptides from subtype I were detected in the
remaining five infected individuals, but it was not possible
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detected mass [M+3H] : 936.4327m/z
calculated mass: 2806.2426 Da









Figure 2 (See legend on next page.)
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Figure 2 Peptide analysis by LC-MS/MS allowing differentiation between BKV-VP1 subtypes. MS/MS analysis of a tryptic peptide
corresponding to aa 39-63 of VP1 distinguished between subtypes (Figure 2A-C). Each panel shows the amino acid sequence for the relevant
viral subtype detected in a clinical isolate. Measured and predicted masses (in brackets) of the b and y fragment ion series are shown within each
spectrum. Amino acids that differ between the subtypes and the corresponding b and y fragment ions are indicated in red. (A) The first peptide
(TGVDAITEVECFLNPEMGDPDENLR) corresponds to the subtypes Ia, Ib-1 and Ic. (B) The second peptide (TGLDAITEVECFLNPEMGDPDENLR) is
specific for subtype Ib-2, whereas (C) the last peptide (TGVDAITEVECFLNPEMGDPDNDLR) is observed in subtype IV only. Subtype Ib-2 (panel B) is
distinguishable from the other subtypes by the presence of a leucine residue instead of a valine residue at position 41, resulting in a
corresponding mass difference of +14 Da in the b ion series from b3 onwards. Subtype IV (panel C) differs from all subtype I variants (panels A
and B) by the presence of asparagine and aspartate instead of glutamate and asparagine at positions 60 and 61 resulting in a corresponding
mass difference of +14 Da in the y ion series from y4 onwards.
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Ib-1, Ic) due to lack of sequence coverage (Table 2).
In eight of the thirteen BK positive individuals
(Table 2), additional peptides were found that had
alternative amino acid substitutions in the sequences
that defined the identified subtype. This data clearly
indicated the presence of an additional strain in these
subjects, i.e. evidence of co-infection. While the
majority of primary infections were due to subgroups
of the subtype I strain (11/13), co-infections tended
to be with subtype IV (5/8) rather than a different
subtype I subgroup (1/8). In the two patients with
primary subtype IV infection, co-infection was with
subtype 1 strains.
To determine whether a correlation existed between
dominant subtypes and severity of infection, cytological
analysis of decoy cells was compared to the data obtained
by mass spectrometry. VP1 was detected in all samples with
more than ten decoy cells (n=11) (Table 2), one sample
with a decoy count of 5–10 and one sample where the
decoy count was negative at the time of mass spectrometry
analysis but had been positive for decoy cells on previous
visits (subject 14). No virus material was detected by MS in
subject 17, who had a decoy cell count under five. This
may also have been due to the fact that a smaller volume of
sample (50%) was available from this subject for the mass
spectrometry analysis. No viral protein was detected by
mass spectrometry in any of the six urine samples from
patients who had been negative for decoy cells throughout
their transplant course. In subject 14 VP1 was detected in
the released viral material fraction, suggesting that viral
material was still being produced although not leading to
effective production of intact virus or the shedding of
infected epithelial cells. This observation suggests that MS
may be a more sensitive measurement of ongoing viral
replication than decoy cell assessment and raises the inter-
esting possibility that not only the presence of viral pep-
tides, but the fraction(s) in which they are found, may have
a bearing on the patient’s response to changes in immuno-
suppression and ultimate clinical outcome.
Interestingly, the three individuals that were Ib-2 positive
demonstrated the highest number of decoy cells (>100),indicating that renal pathology may differ between different
viral subtypes. It would be interesting to investigate this ob-
servation further in a larger cohort. There was no obvious
correlation between co-infection with multiple strains and
decoy cell number. We also investigated the question of the
correlations between viral load within the serum sample,
detected decoy cells in positive urine samples and the mass
spectrometric data (Table 2). The patient with the lowest
detected decoy cell load (<5) also had the lowest viral load
within serum (5×101) and no detectable VP1 peptide by
mass spectrometry. However, overall the viral loads
observed in positive serum samples were from 1.4×103–
3.1×105 with no clear correlation to the decoy cell status
(>10 or >100) of the patient or the BKV VP1 protein
coverage identified by mass spectrometry of urine samples.
A limitation of this study relates to the use of databases
which are comprised of known viral protein sequences.
Peptides produced from novel mutant viral proteins will
not match sequences present in the database and will be
ignored. PCR based techniques face similar problems since
the choice of primers based on known viral sequences may
fail to distinguish between variants or limit detection of un-
known variants. These factors may lead to an underestima-
tion of the extent to which clinical outcome of patients
varies because of differences in the virus subtype(s) present.
A further level of heterogeneity arises from post-
translational modification of viral proteins, which
cannot be detected at all by nucleic acid based
approaches. Such modifications of BKV structural
proteins have been identified by mass spectrometry in
a BKV cell culture model [26]. In our clinical isolates
we also detected modifications consistent with previous
observations, as well as other yet unreported ones (unpub-
lished data). However, the significance of these modifica-
tions in the context of the pathology of BKV and BKVAN
remains to be determined. Simple analysis of our data indi-
cates that in comparison with detection of any decoy cells
in the same urine sample our mass spectrometric approach
has a sensitivity of 93%, a specificity of 87.5%, a positive
predictive value of 93% and a negative predictive value of
87.5%. However, it is arguable that these figures underesti-
mate the utility of this assay since the results from subject















aa unique Peptides detected from co-infection
3 > 10 negative Ic 21% 40–64 K.TGVDAITEVECFLNPEMGDPDENLR.G
173–195 K.YPEGTITPKNPTAQSQVMNTDHK.A
5 >10 3.1×105 Ib-1 74% 171–181 R.TKYPDGTITPK.N IV 40% 94–135 R.IPLPNLNEDLTCGNLLMWEAVTVKTEVI
GITSMLNLHAGSQK.V
7 >100 4.1×103 Ib-2 60% 40–64 K.TGLDAITEVECFLNPEMGDPDENLR.G Ib-1 51% 171–181 R.TKYPDGTITPK.N
8 >10 2.0×104 IV 55% 40–64 K.TGVDAITEVECFLNPEMGDPDNDLR.G Ic 37% 334–349 R.VFDGTEKLPGDPDMIR.Y
9 >100 1.4×103 Ib-2 22% 40–69 K.TGLDAITEVECFLNPEMGDPDE
NLRGFSLK.L
10 <5–10 not done Ib-2,Ic 20% 70–84 K.LSAENDFSSDSPERK.M




13 >100 2.2×104 Ib-2 72% 40–64 K.TGLDAITEVECFLNPEMGDPDENLR.G IV 53% 350–360 R.YIDRQGQLQTK.M
14 negative negative Ib-2 35% 40–64 K.TGLDAITEVECFLNPEMGDPDENLR.G
15 >10 2.4×104 IV 64% 40–64 K.TGVDAITEVECFLNPEMGDPDNDLR.G Ic 42% 334–349 R.VFDGTEKLPGDPDMIR.Y
16 >10 not done Ia, Ib-1 56% 201–215 K.NNAYPVECWVPDPSR.N IV 23% 94–135 R.IPLPNLNEDLTCGNLLMWEAVTVKTEVI
GITSMLNLHAGSQK.V
17 <5 5×101 not detected not detected
18 >10 1.9×104 Ia, Ib-1,Ic 19% 40–69 K.TGVDAITEVECFLNPEMGDPDEN
LRGFSLK.L
19 >10 negative Ia, Ib-1 64% 40–64 K.TGVDAITEVECFLNPEMGDPDENLR.G IV 44% 40–64 K.TGVDAITEVECFLNPEMGDPDNDLR.G
221–256 R.YFGTFTGGENVPPVLHVTNTATTVL
LDEQGVGPLCK.A
For those subjects in whom peptides from VP1 were detected the number of decoy cells, the viral load in serum samples, the dominant viral subtype identified, and percent sequence coverage of VP1 protein are listed. Serum
samples were collected within 2 weeks of the urine sample (except for patient 9 where the interval was 4 months). The peptides identified that defined the dominant viral subtype (based on greater BKV VP1 protein sequence
coverage) are shown. In some cases the presence of two peptides gave evidence for a precise subtype specification. Further, peptides demonstrating the presence of co-infection with a different viral subtype are also shown where
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from subject 14 are more likely to represent a false negative
decoy cell result than a false positive mass spectrometry
result. Our approach yields information about the viral sub-
types present, co-infection and the fractions in which viral
peptides were detected and thus may provide clinically
useful information that goes well beyond a simple diagnosis
of BK viral infection.
Conclusions
BKV infection following renal transplantation remains a
major cause of graft loss and an important clinical problem
[27]. As there is no antiviral drug available, the cornerstone
of management is early detection of infection and cautious
adjustment of immunosuppressive treatment such that the
immune system is able to combat the disease without
provoking kidney graft rejection [28]. Although decoy cell
detection provides some estimate of viral load and activity,
it neither identifies the presence of different viral subtypes
which may vary in their pathogenicity [29] nor provides any
direct estimate of production of intact virus or virus
induced cell lysis. In contrast, in this pilot study, we have
developed a mass spectrometry approach that can detect
viral peptides derived from lysed cells, intact virus, shed
epithelial cells and identify the presence of different sub-
types providing novel leads into disease outcome.
A variety of factors (viral and non-viral) most certainly
contribute to disease severity. However, we provide pre-
liminary evidence that suggests that the subtype Ib-2
infection appears to be related to an elevated number
of decoy cells present in the urine and thus clinical
phenotype.
Overall, we believe these results should stimulate a longi-
tudinal prospective study on a larger cohort to assess corre-
lations between the presence of different viral subtypes, the
fractions in which viral peptides are present and the severity
and course of clinical infection as measured by effects on
graft function.
Methods
Urine sample collection and preparation
20 urine samples were collected from recipients of kidney
transplant (Renal, Transplant and Urology Directorate,
Churchill Hospital, Oxford, U.K.). The average age of the
subjects was 50.75 years and the range was 29–72 (Table 1).
35% of patients were female. The average collection day
post-transplant was 333.25 days with a range of 21–1597
days. Individual immunosuppressive therapies at the time
of urine sampling are listed using the immunosuppressive
indices defined by Vasudev et al (Table 1) [25]. The samples
were kept frozen at −20 degrees until analysis.
A differential centrifugation and filtration protocol was
developed to enrich for viral material. Briefly, 15–35 ml of
urine was centrifuged at~230 g for 10 min at 4°C in aBeckman centrifuge (CS-6R) to pellet cells. After centrifu-
gation, the cell pellet (cellular fraction) was washed twice
with 1 ml of PBS and resuspended in 100 μl of RIPA-Buffer
(50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% NP-40,
0.5% DOC, 0.1% SDS, containing protease inhibitor cocktail
(Roche)). After incubation on ice for 1 hour cells were cen-
trifuged at 16,200 g for 10 min at 4°C and the supernatant
was subjected to methanol / chloroform extraction [30]
and resuspended in 100 μl 6 M Urea in 100 mM Tris
Buffer, pH 7.4. Samples were than digested in solution as
described below. The cell-free viral material was con-
centrated from the supernatant using a 10% sucrose
cushion in PBS by ultracentrifugation at ~ 43,000 g for 3
h at 4°C using a SW 28 rotor (Beckmann Coulter) in a
Beckmann Optima XL-90. The ultracentrifugation pel-
let (intact virus fraction) was resuspended in 100 μl 6 M
Urea in 100 mM Tris Buffer and subjected to in-solu-
tion digestion. Finally, the supernatant was concen-
trated using a 5 kDa cut off filter (Vivaspin, Sartorius),
and this concentrated material (released viral material
fraction) was subjected to methanol / chloroform ex-
traction [30], resuspended in 100 μl 6 M Urea in 100
mM Tris Buffer and subjected to in-solution digestion.
In-solution digestion of the prepared fractions was car-
ried out as follows: The protein mixture was reduced
by the addition of 1 μmol of dithiothreitol (DDT) for
60 min at room temperature and then alkylated by
the addition of iodoacetamide (IAM) (4 μmol) for 60 min
at room temperature. To consume any unreacted iodoace-
tamide, 4 μmol of dithiothreitol was added to the protein
mixture and incubated for another 60 min at room
temperature. The reaction mixture was diluted with 775 μl
of MilliQ water and digestion with 20 ng Trypsin
(Promega) was carried out overnight at 37°C. A Sep-PakW-
Plus C18 column (Waters) purification was carried out to
desalt and concentrate peptides following the manufac-
turer’s instructions, followed by solvent evaporation to
dryness. Samples were resuspended in 20 μl 2% aceto-
nitrile, 0.1% formic acid and kept at −20°C until mass
spectrometry analysis.
Analysis by tandem mass spectrometry
Peptides were analysed by nano-LC-MS/MS using a large
capacity Chip (II), 150 mm 300 Å C18 analytical column
with a 160 nL trap column (Agilent), coupled to an Agi-
lent 6520 quadrupole time-of-flight (Q-Tof) tandem mass
spectrometer. Chromatographic separation of small pep-
tides was performed using a 76 min gradient from 2%
acetonitrile, 0.1% formic acid to 98% acetonitrile, 0.1% for-
mic acid at a flow rate of 600 nl / min. Data were acquired
in MS and MS/MS mode and an inclusion list was gener-
ated to look for specific viral proteins (Additional file 1:
Table S1). Raw data was converted into the Mascot gen-
eric file format (mgf) with Masshunter software (Agilent,
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base where 84 BK viral protein sequences retrieved from
trEMBL/SwissProt were combined with the UniProtKB /
Swiss-Prot (20,287 human sequences) using an in-house
Mascot server (Matrix Science, Version 2.3). The accession
numbers of the BKV VP1 unique sequences are: spP03088
(subtype Ia), trQ65613 (subtype Ib-1), trQ0PCN6 (subtype
Ib-2, E82D, V362L), trA8QZN3 (subtype Ib-2, E82D,
V362L, R340L), trQ65620 (subtype Ic), trQ0PCM5 (subtype
IVa, E77D) and trB6VQF5 (subtype IVc) using subtype
classification based on reference [17].Decoy cell determination
15 ml of urine was centrifuged at 2000 rpm for 5 min.
The pellet was resuspended in 1 ml of diluted Sedfix (10%
Sedfix (Surgipath Europe Ltd, Cambridgeshire) in 45% in-
dustrial methylated spirits (IMS) (Surgipath Europe Ltd,
Cambridgeshire) and deionised water). Slides of fixed cells
were made by centrifuging ten drops of the cell suspen-
sion for 9 min at 850 rpm in a cytospin 3 apparatus
(Shandon Inc., Pittsburgh, Pa). The air-dried cytospin
slides underwent the following staining procedure: slides
were immersed five times in 100% industrial methylated
spirit (IMS) (Surgipath Europe Ltd, Cambridgeshire), and
then immersed in 70% IMS and washed for 30 sec in
water. Slides were incubated for 3 min in Gill’s haema-
toxylin I (Surgipath Europe Ltd, Cambridgeshire) and
were then washed in water for 30 sec. Slides were then
dipped twice in 1% hydrochloric acid (in IMS) and washed
for 2 min in water followed by five washes in 70% and
100% IMS, respectively. After an incubation in OG-6
(Orange G, Surgipath Europe Ltd, Cambridgeshire) for 2
minutes, the slides were washed ten times in 100% IMS.
The slides were incubated in EA-50 for 3 minutes and
then washed again in 100% IMS. Clearing was done in two
changes of Clearene (Surgipath Europe Ltd, Cambridge-
shire) and slides were mounted in DPX (Surgipath Europe
Ltd, Cambridgeshire). A light microscope was used to scan
each slide methodically for BKV positive cells (decoy cells).
The number of decoy cells identified was recorded as 0,
<5, 5–10,> 10 or> 100.Quantitative real time PCR
The assessment of BK viraemia by quantitative real time
PCR was performed at the Health Protection Agency’s
South West Regional Laboratory in Bristol, UK as part
of the routine clinical care of these patients.Additional file
Additional file 1: Table S1. VP1 derived tryptic peptides for detection
by tandem mass spectrometry.Abbreviations
BKV: BK virus; BKVAN: BK virus associated nephropathy; LC-MS/MS: Liquid
chromatography tandem mass spectrometry; VP1: Major capsid protein VP1;
MS: Mass spectrometry.
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